ACS Medicinal Chemistry Letters p. 543 - 547 (2015)
Update date:2022-07-29
Topics:
Li, Yingjun
Cheng, Huimin
Zhang, Zhang
Zhuang, Xiaoxi
Luo, Jinfeng
Long, Huoyou
Zhou, Yang
Xu, Yong
Taghipouran, Rana
Li, Dan
Patterson, Adam
Smaill, Jeff
Tu, Zhengchao
Wu, Donghai
Ren, Xiaomei
Ding, Ke
A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-RafV600E with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-RafV600E mutation while being significantly less potent to the cells with B-RafWT. The compounds also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-RafV600E mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compound for further anticancer drug discovery.
View MoreShandong Yuanli Science and Technology Co., Ltd.
Contact:86-0536-6777557
Address:Zhuliu Industiral Park,Changle County
Chengdu Aslee Biopharmaceuticals, Inc
Contact:18608018419
Address:Chengdu Aslee Biopharmaceuticals, Inc
SHAANXI TOP PHARM CHEMICAL CO.LTD
Contact:+86-029-85733403
Address:No.108 ,west sector,south er huan,xi'an,china
Contact:+86-532-80762375
Address:No. 6, Hongkong Middle Road, Qingdao, China
Lanzhou huibang biological chemical technology Co., LTD
Contact:0931-7843964
Address:NO.2011,Yannan Road,Chengguan,
Doi:10.1007/s11164-012-0654-2
(2013)Doi:10.1002/ejic.201101189
(2012)Doi:10.1007/BF01164718
(1996)Doi:10.1016/0022-328X(91)80073-S
(1991)Doi:10.1021/ja00079a010
(1993)Doi:10.1002/jhet.3557
(2019)